NCT06828887View on ClinicalTrials.gov

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

PHASE2RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

December 20, 2026

Conditions
MDD
Interventions
DRUG

LV232 40mg

LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet

DRUG

LV232 60mg

LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet

DRUG

Escitalopram

LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet

DRUG

Placebo

LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet

Trial Locations (1)

Unknown

RECRUITING

Shanghai Mental Health Center Ethics Committee, Shanghai

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY